Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · February 26, 2022

Risk of Diabetic Ketoacidosis With SGLT2 Inhibitors vs DPP-4 Inhibitors and Sulfonylureas

Diabetes Care

 

Additional Info

Diabetes Care
Comparative Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic Ketoacidosis
Diabetes Care 2022 Feb 11;[EPub Ahead of Print], GK Dawwas, JH Flory, S Hennessy, CE Leonard, JD Lewis

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading